Examining the Frequency of Phlebotomy in Patients with Polycythemia Vera (PV) in the United States: An Analysis of Data from the REVEAL Study
Ralph V. Boccia(Center for Cancer and Blood Disorders), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Pedro Sanz-Altamira(Dana-Farber Cancer Institute), Dilan Paranagama(Incyte (United States)), Ahmad Naim(Incyte (United States)), Khuda Dad Khan(KentuckyOne Health), Dmitriy Berenzon(Atrium Health Wake Forest Baptist), Ellen Friedman(Albert Einstein College of Medicine)
Cited by 4
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
|Journal of Clinical Oncology|2012|461
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425